United States · Bill · S
S. 4378 (117th)
Hatch-Waxman Improvement Act of 2022
Introduced
13 June 2022
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Hatch-Waxman Improvement Act of 2022 This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 13 June 2022
Introduced in Senate (PDF)
Introduced in Senate · EN · 13 June 2022
Introduced in Senate
summary · EN · 13 June 2022
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/4378
- Open data entity: https://api.congress.gov/v3/bill/117/s/4378